Ashish Sharma
@aks-kidneydoc.bsky.social
Kidney Doctor | NSW Health 🇦🇺 |
PhD @UniMelb @TheRMH | Renal Bone Disease | @AKS_KidneyDoc on X
⭐ 🏏 Cricket lover
⭐ 📷 Photography enthusiast
⭐ 🤝 People & meaningful moments
PhD @UniMelb @TheRMH | Renal Bone Disease | @AKS_KidneyDoc on X
⭐ 🏏 Cricket lover
⭐ 📷 Photography enthusiast
⭐ 🤝 People & meaningful moments
Reposted by Ashish Sharma
Renalism: The failure to perform appropriate diagnostic/ therapeutic interventions in patients with CKD due to concern about risk of AKI #Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/15339996/
👉🏼 pubmed.ncbi.nlm.nih.gov/15339996/
October 24, 2025 at 7:42 AM
Renalism: The failure to perform appropriate diagnostic/ therapeutic interventions in patients with CKD due to concern about risk of AKI #Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/15339996/
👉🏼 pubmed.ncbi.nlm.nih.gov/15339996/
Reposted by Ashish Sharma
And the causes of death are heart failure, sudden death, infections- how would fish oil impact those in such a huge way?
It is all a bit puzzling
See @nephroseeker.medsky.social beautiful VA till then
#KidneyWk
It is all a bit puzzling
See @nephroseeker.medsky.social beautiful VA till then
#KidneyWk
November 9, 2025 at 11:49 AM
And the causes of death are heart failure, sudden death, infections- how would fish oil impact those in such a huge way?
It is all a bit puzzling
See @nephroseeker.medsky.social beautiful VA till then
#KidneyWk
It is all a bit puzzling
See @nephroseeker.medsky.social beautiful VA till then
#KidneyWk
Reposted by Ashish Sharma
Reposted by Ashish Sharma
Missing all the overwhelming amount of science coming out of #KidneyWk?
The #NephJC crew has got you covered
Day 2 edition www.nephjc.com/news/kidneyw... via @nephroseeker.medsky.social & moi
The #NephJC crew has got you covered
Day 2 edition www.nephjc.com/news/kidneyw... via @nephroseeker.medsky.social & moi
Kidney Week in Houston: Day 2 — NephJC
in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more
www.nephjc.com
November 8, 2025 at 2:06 PM
Missing all the overwhelming amount of science coming out of #KidneyWk?
The #NephJC crew has got you covered
Day 2 edition www.nephjc.com/news/kidneyw... via @nephroseeker.medsky.social & moi
The #NephJC crew has got you covered
Day 2 edition www.nephjc.com/news/kidneyw... via @nephroseeker.medsky.social & moi
Reposted by Ashish Sharma
And in the evening
- a CAR T in refractory SLE
- a PKD trial
- increasing PD in Vets
- Povetacicept in IgA
- TESTING Longterm term data
- what do the AHA/ACC BP guidelines mean?
#KidneyWk
- a CAR T in refractory SLE
- a PKD trial
- increasing PD in Vets
- Povetacicept in IgA
- TESTING Longterm term data
- what do the AHA/ACC BP guidelines mean?
#KidneyWk
November 8, 2025 at 2:11 PM
And in the evening
- a CAR T in refractory SLE
- a PKD trial
- increasing PD in Vets
- Povetacicept in IgA
- TESTING Longterm term data
- what do the AHA/ACC BP guidelines mean?
#KidneyWk
- a CAR T in refractory SLE
- a PKD trial
- increasing PD in Vets
- Povetacicept in IgA
- TESTING Longterm term data
- what do the AHA/ACC BP guidelines mean?
#KidneyWk
Reposted by Ashish Sharma
Today’s LBCTs and late breaking science!
Morning:
- an Alport trial!
- Telitacicept
- REGENCY biopsy data
- Vitamin R updated in Membranous
- another sibeprenlimab slice
- Balcinrenine + Dapa in CKD
#KidneyWk
Morning:
- an Alport trial!
- Telitacicept
- REGENCY biopsy data
- Vitamin R updated in Membranous
- another sibeprenlimab slice
- Balcinrenine + Dapa in CKD
#KidneyWk
November 8, 2025 at 2:11 PM
Today’s LBCTs and late breaking science!
Morning:
- an Alport trial!
- Telitacicept
- REGENCY biopsy data
- Vitamin R updated in Membranous
- another sibeprenlimab slice
- Balcinrenine + Dapa in CKD
#KidneyWk
Morning:
- an Alport trial!
- Telitacicept
- REGENCY biopsy data
- Vitamin R updated in Membranous
- another sibeprenlimab slice
- Balcinrenine + Dapa in CKD
#KidneyWk
Reposted by Ashish Sharma
Shocking first high impact trial of the day. Fish oil reduces CV events in dialysis patients! #Pisces #kidneywk
Simultaneous pub in NEJM
www.nejm.org/doi/full/10....
Simultaneous pub in NEJM
www.nejm.org/doi/full/10....
November 7, 2025 at 4:45 PM
Shocking first high impact trial of the day. Fish oil reduces CV events in dialysis patients! #Pisces #kidneywk
Simultaneous pub in NEJM
www.nejm.org/doi/full/10....
Simultaneous pub in NEJM
www.nejm.org/doi/full/10....
Reposted by Ashish Sharma
Was listening to nephjc freely filtered episode of ACHIEVE trial just the other day. Of all the things we've tried in HD and failed, and now fish oil does the trick??? @kidneyboy.bsky.social @hswapnil.medsky.social
Shocking first high impact trial of the day. Fish oil reduces CV events in dialysis patients! #Pisces #kidneywk
Simultaneous pub in NEJM
www.nejm.org/doi/full/10....
Simultaneous pub in NEJM
www.nejm.org/doi/full/10....
November 7, 2025 at 11:40 PM
Was listening to nephjc freely filtered episode of ACHIEVE trial just the other day. Of all the things we've tried in HD and failed, and now fish oil does the trick??? @kidneyboy.bsky.social @hswapnil.medsky.social
Reposted by Ashish Sharma
It’s 2025 and we’re still dosing drugs like it’s 1976.
The saga of Cockcroft–Gault, FDA inertia, and the slow evolution of renal dosing equations.
🧮 pbfluids.com/2025/10/cock...
The saga of Cockcroft–Gault, FDA inertia, and the slow evolution of renal dosing equations.
🧮 pbfluids.com/2025/10/cock...
Cockcroft Gault, the latest from the trenches
A few weeks ago I had to check the dose of pregabalin (Lyrica) in kidney failure and found myself in the drug label (this is what happens when you fact check ChatGPT) and saw that they included the…
pbfluids.com
October 26, 2025 at 3:42 PM
It’s 2025 and we’re still dosing drugs like it’s 1976.
The saga of Cockcroft–Gault, FDA inertia, and the slow evolution of renal dosing equations.
🧮 pbfluids.com/2025/10/cock...
The saga of Cockcroft–Gault, FDA inertia, and the slow evolution of renal dosing equations.
🧮 pbfluids.com/2025/10/cock...
Reposted by Ashish Sharma
🚀🖥️ The @nikttaskforce.bsky.social Dashboard Prototype is Live!
🔗 Explore it here: www.niktt.com.au/data-dashboard
📢 We would like to know what you think-please provide feedback here: forms.cloud.microsoft/pages/respon...
📌 Note: The dashboard is best viewed on a desktop computer
🔗 Explore it here: www.niktt.com.au/data-dashboard
📢 We would like to know what you think-please provide feedback here: forms.cloud.microsoft/pages/respon...
📌 Note: The dashboard is best viewed on a desktop computer
September 8, 2025 at 1:05 AM
🚀🖥️ The @nikttaskforce.bsky.social Dashboard Prototype is Live!
🔗 Explore it here: www.niktt.com.au/data-dashboard
📢 We would like to know what you think-please provide feedback here: forms.cloud.microsoft/pages/respon...
📌 Note: The dashboard is best viewed on a desktop computer
🔗 Explore it here: www.niktt.com.au/data-dashboard
📢 We would like to know what you think-please provide feedback here: forms.cloud.microsoft/pages/respon...
📌 Note: The dashboard is best viewed on a desktop computer
Reposted by Ashish Sharma
should we screen for CKD in the general population?
Finally, flozins, finerenone and GLP1s allow a good cost-effectiveness case
www.nephjc.com/news/2025/7/... for #NephJC shorts
Time to stop just being dialysis-ologists and flozinate, glipinate!
#NephSky
Finally, flozins, finerenone and GLP1s allow a good cost-effectiveness case
www.nephjc.com/news/2025/7/... for #NephJC shorts
Time to stop just being dialysis-ologists and flozinate, glipinate!
#NephSky
NephJC Shorts: Should we Screen for Kidney Disease? — NephJC
Should we screen for CKD?
www.nephjc.com
July 31, 2025 at 5:45 PM
should we screen for CKD in the general population?
Finally, flozins, finerenone and GLP1s allow a good cost-effectiveness case
www.nephjc.com/news/2025/7/... for #NephJC shorts
Time to stop just being dialysis-ologists and flozinate, glipinate!
#NephSky
Finally, flozins, finerenone and GLP1s allow a good cost-effectiveness case
www.nephjc.com/news/2025/7/... for #NephJC shorts
Time to stop just being dialysis-ologists and flozinate, glipinate!
#NephSky
Reposted by Ashish Sharma
Algorithmic approach to Peritoneal Dialysis (PD) Catheter OUTFLOW FAILURE
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/20630641/
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/20630641/
July 12, 2025 at 7:23 PM
Algorithmic approach to Peritoneal Dialysis (PD) Catheter OUTFLOW FAILURE
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/20630641/
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/20630641/
Reposted by Ashish Sharma
CKD-MBD still undefeated in its ability to generate negative trials!
This study sounds like a three-foot putt. How can sevelamer not be better at reducing propensity toward calcification? I don't know but P=0.8.
This study sounds like a three-foot putt. How can sevelamer not be better at reducing propensity toward calcification? I don't know but P=0.8.
The effect of sevelamer on serum calcification propensity in patients with chronic kidney disease:
the results of a multicentre, double-blind, placebo-controlled, randomized clinical trial
doi.org/10.1093/ckj/...
the results of a multicentre, double-blind, placebo-controlled, randomized clinical trial
doi.org/10.1093/ckj/...
April 18, 2025 at 1:31 PM
CKD-MBD still undefeated in its ability to generate negative trials!
This study sounds like a three-foot putt. How can sevelamer not be better at reducing propensity toward calcification? I don't know but P=0.8.
This study sounds like a three-foot putt. How can sevelamer not be better at reducing propensity toward calcification? I don't know but P=0.8.
Reposted by Ashish Sharma
HELLO I HAVE A ROUTINE CONSULT THEY CAN BE SEEN IN THE MORNING JUST WANNA LET YOU KNOW ABOUT IT NOW AT MIDNIGHT OKAY THANKS GOODNIGHT
April 6, 2025 at 5:01 AM
HELLO I HAVE A ROUTINE CONSULT THEY CAN BE SEEN IN THE MORNING JUST WANNA LET YOU KNOW ABOUT IT NOW AT MIDNIGHT OKAY THANKS GOODNIGHT
Reposted by Ashish Sharma
consulted for a potassium of 5.5 on a patient who recently started both entresto and aldactone. i am a salieri in a world with no mozarts.
April 5, 2025 at 2:23 PM
consulted for a potassium of 5.5 on a patient who recently started both entresto and aldactone. i am a salieri in a world with no mozarts.
Reposted by Ashish Sharma
Work smarter, not harder!
A low renin with concurrent use of ACEi/ARB is almost certainly some shade of Primary Aldosteronism.
Either way, aldosterone-directed therapy is very likely to provide major clinical benefits
www.ahajournals.org/eprint/TUS6C...
A low renin with concurrent use of ACEi/ARB is almost certainly some shade of Primary Aldosteronism.
Either way, aldosterone-directed therapy is very likely to provide major clinical benefits
www.ahajournals.org/eprint/TUS6C...
April 3, 2025 at 1:09 AM
Work smarter, not harder!
A low renin with concurrent use of ACEi/ARB is almost certainly some shade of Primary Aldosteronism.
Either way, aldosterone-directed therapy is very likely to provide major clinical benefits
www.ahajournals.org/eprint/TUS6C...
A low renin with concurrent use of ACEi/ARB is almost certainly some shade of Primary Aldosteronism.
Either way, aldosterone-directed therapy is very likely to provide major clinical benefits
www.ahajournals.org/eprint/TUS6C...
Reposted by Ashish Sharma
FRESH-UP Trial #ACC25 #medsky
RCT comparing liberal vs restricted fluid intake (≤1500 ml/d) in 504 pts with stable chronic HF
🌊No difference in status health quantified by Kansas City Cardiomyopathy Questionnaire at 3 mths
🌊 More thirst distress with restriction
www.nature.com/articles/s41...
RCT comparing liberal vs restricted fluid intake (≤1500 ml/d) in 504 pts with stable chronic HF
🌊No difference in status health quantified by Kansas City Cardiomyopathy Questionnaire at 3 mths
🌊 More thirst distress with restriction
www.nature.com/articles/s41...
March 30, 2025 at 8:50 PM
FRESH-UP Trial #ACC25 #medsky
RCT comparing liberal vs restricted fluid intake (≤1500 ml/d) in 504 pts with stable chronic HF
🌊No difference in status health quantified by Kansas City Cardiomyopathy Questionnaire at 3 mths
🌊 More thirst distress with restriction
www.nature.com/articles/s41...
RCT comparing liberal vs restricted fluid intake (≤1500 ml/d) in 504 pts with stable chronic HF
🌊No difference in status health quantified by Kansas City Cardiomyopathy Questionnaire at 3 mths
🌊 More thirst distress with restriction
www.nature.com/articles/s41...
Reposted by Ashish Sharma
People look at this and scream about getting an AV accesses because of the dramatically lower infection rate, but 1.2 infections per 100 patient-years is 1.2 blood stream infections per patient per 8.8 years
We have bigger fish to fry in dialysis than one BSI per decade.
We have bigger fish to fry in dialysis than one BSI per decade.
March 31, 2025 at 1:42 AM
People look at this and scream about getting an AV accesses because of the dramatically lower infection rate, but 1.2 infections per 100 patient-years is 1.2 blood stream infections per patient per 8.8 years
We have bigger fish to fry in dialysis than one BSI per decade.
We have bigger fish to fry in dialysis than one BSI per decade.
Reposted by Ashish Sharma
The oral sema results are interesting
Difficult to comment indirectly, but seems less impressive than injectable sema?
Lot of kidney and HF events and favourable point estimates but not a huge effect
#ACC25
Difficult to comment indirectly, but seems less impressive than injectable sema?
Lot of kidney and HF events and favourable point estimates but not a huge effect
#ACC25
March 29, 2025 at 9:51 PM
The oral sema results are interesting
Difficult to comment indirectly, but seems less impressive than injectable sema?
Lot of kidney and HF events and favourable point estimates but not a huge effect
#ACC25
Difficult to comment indirectly, but seems less impressive than injectable sema?
Lot of kidney and HF events and favourable point estimates but not a huge effect
#ACC25
Reposted by Ashish Sharma
Although I suppose that the newly published meta-analysis is the counterpoint.
March 29, 2025 at 10:24 PM
Although I suppose that the newly published meta-analysis is the counterpoint.
Reposted by Ashish Sharma
Starter packs may be passé - but we have had an influx, and we now have a 1/3rd full 6th nephrology pack
5th pack go.bsky.app/JJ4h8su
4th pack: go.bsky.app/YeuH82
3rd pack: go.bsky.app/2yLiYN4
2nd pack go.bsky.app/N27Kzri
1st pack: go.bsky.app/H4td28C
6th go.bsky.app/Gsm6BeJ
#NephSky
5th pack go.bsky.app/JJ4h8su
4th pack: go.bsky.app/YeuH82
3rd pack: go.bsky.app/2yLiYN4
2nd pack go.bsky.app/N27Kzri
1st pack: go.bsky.app/H4td28C
6th go.bsky.app/Gsm6BeJ
#NephSky
March 28, 2025 at 2:24 PM
Starter packs may be passé - but we have had an influx, and we now have a 1/3rd full 6th nephrology pack
5th pack go.bsky.app/JJ4h8su
4th pack: go.bsky.app/YeuH82
3rd pack: go.bsky.app/2yLiYN4
2nd pack go.bsky.app/N27Kzri
1st pack: go.bsky.app/H4td28C
6th go.bsky.app/Gsm6BeJ
#NephSky
5th pack go.bsky.app/JJ4h8su
4th pack: go.bsky.app/YeuH82
3rd pack: go.bsky.app/2yLiYN4
2nd pack go.bsky.app/N27Kzri
1st pack: go.bsky.app/H4td28C
6th go.bsky.app/Gsm6BeJ
#NephSky
Reposted by Ashish Sharma
Also note two large RCTs ongoing - or about to start - in France: bsky.app/profile/dgue...
Hi Swapnil, as you may know 2 large RCTs, DAPA-PKD & STOP-PKD have secured academic funding to evaluate the use of SGLT2i in ADPKD. They are set to launch in 2026.
Upon completion, both trials will combine their datasets in a pooled analysis, called FLOZIN-PKD. Hope you like the name 😉
Upon completion, both trials will combine their datasets in a pooled analysis, called FLOZIN-PKD. Hope you like the name 😉
March 23, 2025 at 1:46 AM
Also note two large RCTs ongoing - or about to start - in France: bsky.app/profile/dgue...
Reposted by Ashish Sharma
We also recently transitioned a pt to both - incremental HDF 💧💦 Some are very CONVINCEd in our dept but we may INCH closer to finding an answer #AKTN aktn.org.au/inch-hd/ pubmed.ncbi.nlm.nih.gov/36938090/ @sarahkmels.bsky.social @nephmadness.bsky.social
INCH-HD - Australasian Kidney Trials Network (AKTN)
The INCremental dialysis to improve Health outcomes in people starting Haemodialysis (INCH-HD) study: a randomised controlled trial
aktn.org.au
March 21, 2025 at 9:07 PM
We also recently transitioned a pt to both - incremental HDF 💧💦 Some are very CONVINCEd in our dept but we may INCH closer to finding an answer #AKTN aktn.org.au/inch-hd/ pubmed.ncbi.nlm.nih.gov/36938090/ @sarahkmels.bsky.social @nephmadness.bsky.social
Reposted by Ashish Sharma
#Quiz: A man in his 40s with untreated hypertension presented with right-sided neurologic deficits and slurred speech. His hypertension & age prompted investigation for a secondary etiology of his hypertension. What is the differential diagnosis?
bit.ly/3gyO2ie (FREE)
bit.ly/3gyO2ie (FREE)
March 15, 2025 at 10:00 AM
#Quiz: A man in his 40s with untreated hypertension presented with right-sided neurologic deficits and slurred speech. His hypertension & age prompted investigation for a secondary etiology of his hypertension. What is the differential diagnosis?
bit.ly/3gyO2ie (FREE)
bit.ly/3gyO2ie (FREE)